GILD - Company ID 0000882095
The table below shows GILEAD SCIENCES, INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $6.96B | $7.77B | $7.08B | $6.67B | $7.54B | $6.95B |
| Cost of revenue | $1.45B | $1.57B | $1.50B | $1.54B | $1.57B | $1.54B |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
GILEAD SCIENCES, INC. reported annual revenue of $29.44B for fiscal year 2025. That is up 2.4% from $28.75B in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $30.39B (FY 2016) to $29.44B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $1.45B |
| $1.36B |
| $1.36B |
| $1.26B |
| $1.43B |
| $1.38B |
| Operating income | $2.59B | $3.33B | $2.47B | $2.24B | $888.00M | $2.64B |
| Income tax | $559.00M | $589.00M | $468.00M | $334.00M | -$297.00M | $438.00M |
| Net income | $2.02B | $3.05B | $1.96B | $1.31B | $1.25B | $1.61B |
| EPS (diluted) | $1.61 | $2.43 | $1.56 | $1.04 | $1.00 | $1.29 |